Downregulation of Checkpoint Protein Kinase 2 in the Urothelium of Healthy Male Tobacco Smokers by Breyer, Johannes et al.
E-Mail karger@karger.com
 Letter to the Editor 
 Urol Int 2016;97:480–481 
 DOI: 10.1159/000446827 
 Downregulation of Checkpoint Protein 
Kinase 2 in the Urothelium of Healthy Male 
Tobacco Smokers 
 Johannes Breyer  a    Stefan Denzinger  a    Arndt Hartmann  b    Wolfgang Otto  a 
 a   Department of Urology, Medical Center St. Josef, Regensburg University Medical Center,  Regensburg , and 
 b   Institute of Pathology, Friedrich-Alexander University of Erlangen-Nuremberg,  Erlangen , Germany 
smokers had a 7.4-fold risk to develop 
UBC, while former smokers still had a 
nearly 4 times higher UBC incidence than 
non-smokers. While overall there was no 
statistically significant decrease of UBC 
risk in former smokers, quitting the habit 
of smoking blond tobacco for more than 10 
years led to a statistically significant lower 
tumor incidence compared to current 
smokers  [2] .
 The difference between blond and black 
tobacco lies in black tobacco’s much higher 
concentration of N-nitrosamine and 
2-naphthylamine. However, it is unknown 
how these substances bring about carcino-
genesis in detail. It would be most valuable 
to study the consequences of tobacco smok-
ing on histopathologically normal urothe-
lium to recognize very early molecular al-
terations. In the present preliminary study, 
we performed an immunohistochemical 
analysis of healthy male urothelium of cur-
rent, former and non-smokers without his-
topathological signs of urothelial changes 
for the first time in vivo and identified ex-
pression of checkpoint protein kinase 2 
(CHEK2). To repair cellular damages by 
carcinogens, protein kinases like CHEK2 
are activated to introduce repair mecha-
nisms and stop cell cycle until the damage 
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 Abstract 
 With this letter to the editor we present for 
the first time a study on CHEK2 expression in 
normal urothelium of healthy male smokers, 
former smokers and non-smokers. We could 
show a statistically significant downregula-
tion of this DNA repair gene in current smok-
ers compared to non-smokers, suggesting 
that smoking downregulates CHEK2 in nor-
mal urothelium, probably associated with 
an early step in carcinogenesis of urothelial 
bladder carcinoma.  © 2016 S. Karger AG, Basel 
 Urothelial bladder carcinoma (UBC) 
belongs to the 5 most frequent tumors oc-
curring worldwide. In a recent meta-anal-
ysis, Burger et al.  [1] confirmed that about 
50% of all bladder tumors are derived from 
tobacco smoking. Samanic et al.  [2] ana-
lyzed a collective of 2,500 patients in Spain, 
where UBC incidence among men is the 
highest in the whole EU  [1, 2] . Current 
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is repaired. Downregulation of CHEK2 has 
been proven in various neoplasms, for ex-
ample, lung cancer, to be associated with 
worse outcome  [3] . Germline mutations in 
CHEK2 are reported to be associated with 
an increased risk of bladder cancer  [4] .
 After patients’ informed consent fol-
lowing a positive vote of the local Ethics 
Committee at Regensburg University, 
macroscopic unsuspicious urothelial spec-
imens of the bladder were taken from 92 
male patients during transurethral resec-
tion of the prostate. Samples were assessed 
by an experienced uropathologist (A.H.) 
and revealed normal urothelium without 
histomorphological changes. A tissue mi-
cro array was constructed and stained with 
CHEK2 protein kinase antibody (mouse 
mAB 3440, dilution 1: 3,200). As in previ-
ous immunohistochemical analyses on 
CHEK2, we compared negative and weak 
to moderate and strong staining ( fig. 1 a, b).
 Of 92 patients (median age 70, IC 64–76 
years), 45% (n = 41) did never smoke, 43% 
(n = 40) stopped smoking at least one year 
ago and 12% (n = 11) were current tobacco 
smokers. Moderate and strong staining of 
CHEK2 was shown in 44% of non-smokers 
but only in 9% of current smokers with a 
statistically significant difference (p = 
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0.032), while former smokers regained a 
higher rate of CHEK2 expression (30%; 
 fig. 1 c). This suggests that tobacco smoking 
downregulates CHEK2. This might be a 
first step in the development of urothelial 
neoplasms. There was no statistically sig-
nificant difference in the expression of 
CHEK2 between former smokers and non-
smokers suggesting that effects of tobacco 
smoking on CHEK2 expression are revers-
ible, when smoking is stopped. Further 
studies on the effects of tobacco on human 
urothelium are needed to reveal the very 
first steps of tobacco-derived carcinogene-
sis in the urothelium. 
 Fig. 1.  a–c Examples of negative ( a ) and 
strong positive expression ( b ) of CHEK2 in 
urothelial cells of healthy male patients 
(40-fold magnification).  c Percentage of 
moderate and strong expression of CHEK2 
in urothelial specimens of non-smokers 
(ns), former smokers (fs) and current 
smokers (cs). Statistically significant p val-
ues in bold. 
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